CSPC Innovation Pharmaceutical (SHE:300765) unit CSPC Jushi Biopharmaceutical obtained the approval of China's medical products administrator to conduct clinical trials for SYS6041 in combination therapy for ovarian cancer.
The potential indications for SYS6041 include solid tumors such as gynecological tumors and lung cancer, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 4% lower Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments